IL1A alleles associate with a virological response to antiretroviral therapy in HIV patients beginning therapy with advanced disease

AIDS. 2009 Jun 1;23(9):1173-6. doi: 10.1097/qad.0b013e32832c4118.

Abstract

Among Australians treated for advanced HIV disease, a suboptimal virological response was associated with allele 2 at interleukin 1 alpha (IL1A)-889 and IL1A+4845. This is confirmed and investigated using patients from AIDS Clinical Trials Group study 384 (n=532). Among non-African-American patients with CD4 T-cell count of< or = 100 cells/microl at baseline, IL1A+4845(*)TT was associated with poor virological outcome (P=0.03). Differences were smaller with higher baseline CD4 T-cell counts. IL1A-889 and IL1A+4845 were not in linkage disequilibrium in African-American patients, and IL1A+4845(*)T did not affect outcome.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antiretroviral Therapy, Highly Active*
  • CD4 Lymphocyte Count
  • Female
  • Genetic Linkage
  • HIV Infections / drug therapy
  • HIV Infections / genetics*
  • HIV-1 / genetics*
  • Humans
  • Interleukin-1alpha / genetics*
  • Male
  • RNA, Viral / genetics*

Substances

  • Interleukin-1alpha
  • RNA, Viral